



Public Health  
England

Protecting and improving the nation's health

# Cancer Outcomes and Services Dataset (COSD)

Version 8.0

## Change Request

## About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

Public Health England  
Wellington House  
133-155 Waterloo Road  
London SE1 8UG  
Tel: 020 7654 8000  
[www.gov.uk/phe](http://www.gov.uk/phe)  
Twitter: [@PHE\\_uk](https://twitter.com/PHE_uk)  
Facebook: [www.facebook.com/PublicHealthEngland](https://www.facebook.com/PublicHealthEngland)

© Crown copyright 2017

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](https://www.nationalarchives.gov.uk/ogl/) or email [psi@nationalarchives.gsi.gov.uk](mailto:psi@nationalarchives.gsi.gov.uk). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published: September 2017  
PHE publications  
gateway number: 2017376

PHE supports the UN  
Sustainable Development Goals





## Data Coordination Board

This information standard (DCB1521) has been approved for publication by the Department of Health under [section 250 of the Health and Social Care Act 2012](#).

Assurance that this information standard meets the requirements of the Act and is appropriate for the use specified in the specification document has been provided by the Data Coordination Board (DCB), a sub-group of the Digital Delivery Board.

This information standard comprises the following documents:

- Specification
- Implementation Guide
- Change Request.

An Information Standards Notice (DCB1521 Amd 74/2016) has been issued as a notification of use and implementation timescales. Please read this alongside the documents for the standard.

The controlled versions of these documents can be found on the [NHS Digital website](#). Any copies held outside of that area, in whatever format (e.g. paper, email attachment), are considered to have passed out of control and should be checked for currency and validity.

Date of publication: 28 September 2017.

<b>Title</b>	Cancer Outcomes and Services Data set (COSD) version 8.0 – Change Request		
<b>SCCI reference</b>	DCB1521 Amd 74/2016		
<b>Sponsor</b>	Dr Jem Rashbass	<b>Status</b>	Final
<b>Senior responsible officer</b>	Professor John Newton	<b>Version</b>	8.0
<b>Author(s)</b>	Andrew Murphy	<b>Version Date</b>	05/05/2017

#### Amendment History:

Version	Date	Amendment history
3.0	31-05-2017	Updated draft for DSAS assessment (COSD v8.0)
3.1	21-07-2017	Updated draft for DSAS assessment (COSD v8.0)
3.2	11-08-2017	Final for Publication (post editorial comments)
3.3	23-08-2017	Final for Publication (post additional editorial comments)

#### Approvals:

Name	Organisation	Version	Date
COSD Advisory Board	Cross Organisation Board	8.0	21-04-2017
COSD Governance Board	Cross Organisation Board, reporting to Professor Chris Harrison, National Clinical Director (NHS England) and Dr Jem Rashbass, Director for National Disease Registration (Public Health England)	8.0	25-04-2017

#### Related Documents:

Ref #	Doc Reference	Title	Version	Date
1	COSD Specification <sup>1</sup>	COSD Specification	8.0	21-07-2017

<sup>1</sup> [www.content.digital.nhs.uk/isce/publication/dcb1521](http://www.content.digital.nhs.uk/isce/publication/dcb1521)

## Contents

<b>1</b>	<b>Overview</b> .....	<b>7</b>
1.1	Summary .....	7
1.2	Supporting products .....	9
1.3	Related standards .....	9
<b>2</b>	<b>Change specification</b> .....	<b>11</b>
2.1	New items.....	12
2.2	Amendments .....	14
2.2.1	Substantial amendment changes .....	14
2.2.2	Cosmetic amendment changes .....	17
2.2.3	Schema Mandation amendment changes .....	24
2.3	Deletions .....	25
2.4	Extension of scope .....	30

# 1 Overview

## 1.1 Summary

Standard	
Standard number	DCB1521
Standard title	Cancer Outcomes and Services Data set (COSD)
Release	
Release number	Amd 74/2016
Release title	Version 8.0
Description	<p>This is a change to the Cancer Outcomes and Services Data set (COSD) standard which builds on the work started in v7.0 and introduces some new amendments and re-alignments to the current data set, and a revision of the current schema specification in order to continue to meet the business objectives of the standard.</p> <p>Extensive consultation was conducted over a 6 month period with 47 key groups or clinical experts, including all the Site Specific Clinical Reference Groups<sup>2</sup> (SSCRGs), experts from within the National Cancer Registration and Analysis Service<sup>3</sup> (NCRAS), as well as Clinical Support and Advice from the chair of the Royal College of Pathologists Working Group on Cancer Services. For the first time, cancer charities and patient groups were also consulted upon.</p> <p>This process completes the work started in 2016 and allowed the data set to be clinically reviewed, validated and updated by experts in all fields of cancer and provide a clinically sound set of data to be collected from 2018 onwards, which meets crucial recommendations in the Achieving World-Class Cancer Outcomes, A Strategy for England 2015-2020 (Cancer Taskforce Report)<sup>4</sup>.</p> <p><b><u>The changes are:</u></b></p> <p><b>Relax mandation:</b> In order to prevent valid data being withheld due to the reporting methodology of XML, the schema specification continues to be relaxed (as per v7.0) for all data (except linkage items) from 'mandatory' to 'required'. This will support registration processes and provide early identification of gaps in data.</p>

<sup>2</sup> The Site Specific Clinical Reference Groups are tumour specific, nationally recognised expert groups who agree and set the agenda for cancer data and analysis within their field in the NHS.

<sup>3</sup> The NCRAS now includes the National Cancer Intelligence Network (NCIN)

<sup>4</sup> <http://www.cancerresearchuk.org/about-us/cancer-strategy-in-england>

	<p><b>Extend scope:</b> There is a continued commitment within v8.0 to encourage Trusts to record all recurrences, and a new recording pathway has been introduced with clearer more accurate data items to support the recommendations within the Cancer Taskforce Report.</p> <p><b>Changes to data set:</b> In order to align with current business needs and clinical practice and to support data quality, various changes have been made to the data set as follows:</p> <p><b>39 new data items have been added</b> most of these data are either collected already in cancer management systems or within the Multi-disciplinary Team (MDT) and have been heavily consulted upon with the Site Specific Clinical Reference Groups. Of which:</p> <ul style="list-style-type: none"> <li><b>1 data item has been added</b>, which complies with the Information Standard SCCI2094 on sexual orientation.</li> <li><b>13 data items have been added</b>, to create a new section for the accurate collection of data for Liver tumours.</li> <li><b>3 data items have been added</b>, to create a new section for the accurate collection of risk factors.</li> <li><b>1 data item has been added</b>, which complies with the Information Standard SCCI0034 on SNOMED CT diagnosis.</li> </ul> <p><b>92 data items have been deleted</b> of which 18 were to remove duplication within the data set, whilst 48 were to remove linked data collected in other national data sets. Of which:</p> <ul style="list-style-type: none"> <li><b>6 Pathology data items have been deleted</b> to reduce duplication or to align with revisions to Royal College of Pathologists (RC Path) core data sets.</li> </ul> <p><b>57 data items have been re-aligned or moved</b> within the data set. This ensures that data nests correctly within the XML and will help with data collection, quality and ascertainment.</p> <p><b>51 data items have been amended</b> for better synchronisation across the NHS Data Model and Dictionary, to allow for changes in new staging systems and/or for clarification of descriptions and should improve the collection of the standard. Of which:</p> <ul style="list-style-type: none"> <li><b>11 data items have been updated</b> to meet the new requirement due to the new Health and Social Care Organisation Reference Data standard (ANANA) - SCCI0090.</li> </ul>
Implementation start and completion date	<p>Implementation will be between 29/09/2017 and 31/03/2018 (6 months).</p> <p>Data collection will start from 01/04/2018 (with a three month roll-out period between 01/04/2018 and 30/06/2018).</p> <p>Full conformance from 01/07/2018 (reported in the July batch within the September upload).</p>

## 1.2 Supporting products

Product	Document Reference	Title
Change Request	<a href="http://www.content.digital.nhs.uk/isce/publication/dcb1521">www.content.digital.nhs.uk/isce/publication/dcb1521</a>	Change Request
COSD Data set v8.0	<a href="http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd">http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd</a>	COSD data set 8.0
COSD Data set v8.0, Pathology v3.0	<a href="http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd">http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd</a>	COSD data set 8.0, Pathology v3.0
COSD v8.0 user guide	<a href="http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd">http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd</a>	COSD v8.0 user guide
COSD v8.0 Pathology data set v3.0 user guide	<a href="http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd">http://www.ncin.org.uk/collecting_and_using_data/data_collection/cosd</a>	COSD v8.0 Pathology data set v3.0 user guide
Implementation Guide	<a href="http://www.content.digital.nhs.uk/isce/publication/dcb1521">www.content.digital.nhs.uk/isce/publication/dcb1521</a>	Implementation Guide

## 1.3 Related standards

Ref #	Reference	Title
DCB0147	<a href="http://content.digital.nhs.uk/isce/publication/DCB0147">http://content.digital.nhs.uk/isce/publication/DCB0147</a>	National Cancer Waiting Times Data set
SCCI0111	<a href="http://content.digital.nhs.uk/isce/publication/SCCI0111">http://content.digital.nhs.uk/isce/publication/SCCI0111</a>	Radiotherapy Data Set
ISB 1533	<a href="http://www.isb.nhs.uk/documents/isb-1533/amd-63-2010/index.html">http://www.isb.nhs.uk/documents/isb-1533/amd-63-2010/index.html</a>	Systemic Anti-Cancer Therapy Data Set
SCCI1577	<a href="http://content.digital.nhs.uk/isce/publication/scci1577">http://content.digital.nhs.uk/isce/publication/scci1577</a>	Diagnostic Imaging Data Set
SCCI0021	<a href="http://content.digital.nhs.uk/isce/publication/SCCI0021">http://content.digital.nhs.uk/isce/publication/SCCI0021</a>	International Statistical Classification of Diseases and Health Related Problems (ICD-10)

SCCI0034	<a href="http://content.digital.nhs.uk/isce/publication/scci0034">http://content.digital.nhs.uk/isce/publication/scci0034</a>	SNOMED CT
n/a	<a href="http://www.rcpath.org/professional-standards">http://www.rcpath.org/professional-standards</a>	Royal College of Pathologists professional standards

## 2 Change specification

This is a complex data set covering 200 diseases and requiring alignment with changing clinical practice. It is therefore expected that regular changes will be required. The current new items reflect this and are introduced to align with current business needs and clinical practice, and to support data quality.

New data items have been added after extensive consultation was conducted with all the Site Specific Clinical Reference Groups (SSCRGs), experts from within the National Cancer Registration and Analysis Service (NCRAS), as well as clinical support and advice from the chair of the Royal College of Pathologists Working Group on Cancer Services. Details of the consultation process were provided as supporting evidence to the Data Coordination Board (DCB) in the Consultation Plan document.

Many of the data within COSD were changed in 2016 and this revision completes the work started in v7.0. This thorough process allowed the data set to be clinically reviewed, validated and updated by experts in all fields of cancer and provide a clinically sound set of data to be collected from 2018 onwards.

The Achieving World-Class Cancer Outcomes, A Strategy for England 2015-2020 (Cancer Taskforce Report)<sup>5</sup>, produced a series of recommendations of which 7 directly impacted upon COSD. The strategy pointed out the need for changes - which have been interpreted and applied to the data set and new data items have been included within v8.0 to support these recommendations.

In addition there are new data to help identify and analyse:

- risk factors
- liver tumours
  - A whole new section has been added at the request and guidance of Liver specialists
- recurrence, progression and transformation, both as part of the 'Primary Pathway' and within the new 'Non-Primary Cancer Pathway'
  - the old recurrence pathway has been removed and replaced with a more accurate 'Non-Primary Cancer Pathway'
- metastatic disease

Many data have been re-aligned across the data set into the correct higher level groupings, especially around Children, Teenage and Young Adults (CTYA).

The data set can now be easily maintained within each Trust, by using one of two subsets (depending on the department responsible for each data collection process):

- Pathology - This was part of the last version of the standard and is now mandated across all Trusts to supply these data in COSD XML directly from their pathology departments
  - this is different from the main 'patient pathway' COSD data set as there are unique linkages for pathology and therefore requires its own unique schema

---

<sup>5</sup> [https://www.cancerresearchuk.org/sites/default/files/achieving\\_world-class\\_cancer\\_outcomes\\_-\\_a\\_strategy\\_for\\_england\\_2015-2020.pdf](https://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf)

- Patient Pathway - This is the data, excluding Pathology, which the Cancer Services Teams need to collect. By removing the pathology data from their workload, it reduces their burden of data collection by up-to 30% across the whole data set
  - as pathology data continues to be collected by the pathologists and reported by the pathology departments (using structured COSD XML), it is not expected that the MDT Coordinators/Pathway Coordinators or Cancer Services Teams will be required to duplicate this 'clinical' data collection
    - this is expected to reduce the burden of data collection for the Cancer Teams at Trusts

## 2.1 New items

Full details of all the new items (listed below) are provided in the COSD Data set v8.0 and COSD User Guide v8.0

- **DATE OF NON PRIMARY CANCER DIAGNOSIS (CLINICALLY AGREED)**
  - *CORE - DIAGNOSTIC DETAILS*
- **NON PRIMARY CANCER PATHWAY**
  - *CORE - NON PRIMARY CANCER PATHWAY ROUTE*
- **RECURRENCE OR METASTATIC TYPE**
  - *CORE - NON PRIMARY CANCER PATHWAY ROUTE*
- **PROGRESSION (ICD)**
  - *CORE - NON PRIMARY CANCER PATHWAY ROUTE*
- **PERSON SEXUAL ORIENTATION CODE (AT DIAGNOSIS)**
  - *CORE - DEMOGRAPHICS*
- **IMAGING OUTCOME**
  - *CORE - IMAGING*
- **DIAGNOSIS CODE (SNOMED CT)**
  - *CORE - DIAGNOSIS*
- **METASTATIC TYPE**
  - *CORE - DIAGNOSIS*
- **PROGRESSION DATE (PRIMARY PATHWAY)**
  - *CORE - DIAGNOSIS*
- **SNOMED VERSION (TRANSFORMATION)**
  - *CORE - DIAGNOSIS*
- **MORPHOLOGY (SNOMED) TRANSFORMATION**
  - *CORE - DIAGNOSIS*
- **MORPHOLOGY (ICDO3)\* TRANSFORMATION**
  - *CORE - DIAGNOSIS*
- **TRANSFORMATION DATE (PRIMARY PATHWAY)**
  - *CORE - DIAGNOSIS*
- **SMOKING STATUS**
  - *CORE - CLINICAL NURSE SPECIALIST + RISK FACTOR ASSESSMENT*
- **HISTORY OF ALCOHOL (CURRENT)**
  - *CORE - CLINICAL NURSE SPECIALIST + RISK FACTOR ASSESSMENT*
- **HISTORY OF ALCOHOL (PAST)**
  - *CORE - CLINICAL NURSE SPECIALIST + RISK FACTOR ASSESSMENT*

- **CLINICAL TRIAL DECISION DATE (PATIENT)**
  - *CORE - CLINICAL TRIALS*
- **DATE CLINICAL TRIAL STARTED**
  - *CORE - CLINICAL TRIALS*
- **ORGANISATION SITE IDENTIFIER (REPORTED PRETREATMENT TNM STAGE)**
  - *CORE - STAGING*
- **ORGANISATION SITE IDENTIFIER (REPORTED INTEGRATED TNM STAGE)**
  - *CORE - STAGING*
- **TNM CODING EDITION**
  - *CORE - STAGING*
- **ADJUNCTIVE THERAPY**
  - *CORE - TREATMENT*
- **TNM CODING EDITION**
  - *CORE - PATHOLOGY DETAILS*
- **TNM VERSION NUMBER (PATHOLOGICAL)**
  - *CORE - PATHOLOGY DETAILS*
- **GRADE OF DIFFERENTIATION (COLORECTAL PATHOLOGICAL)**
  - *COLORECTAL - PATHOLOGY*
- **MENOPAUSAL STATUS**
  - *BREAST - DIAGNOSIS*
- **CARE CONTACT DATE (SLT INITIAL)**
  - *HEAD & NECK - PRE TREATMENT ASSESSMENT*
- **LIVER SURVEILLANCE SCANS**
  - *LIVER - DIAGNOSIS*
- **LIVER CIRRHOSIS TYPE**
  - *LIVER - DIAGNOSIS*
- **CAUSE OF LIVER CIRRHOSIS**
  - *LIVER - DIAGNOSIS*
- **DIABETES INDICATOR**
  - *LIVER - DIAGNOSIS*
- **UKELD SCORE**
  - *LIVER - STAGING*
- **HCC EMBOLISATION**
  - *LIVER - TREATMENT - LIVER METS & LIVER HCC*
- **EMBOISATION MODALITY**
  - *LIVER - TREATMENT - LIVER METS & LIVER HCC*
- **LIVER TRANSPLANTATION**
  - *LIVER - SURGERY AND OTHER PROCEDURES*
- **SURGERY TYPE**
  - *LIVER - SURGERY AND OTHER PROCEDURES*
- **PROSTATE BIOPSY TECHNIQUE**
  - *UROLOGICAL - DIAGNOSIS - PROSTATE*
- **PROCEDURE - NERVE SPARING**
  - *UROLOGICAL - TREATMENT - PROSTATE*
- **RADICAL PROSTATECTOMY MARGIN STATUS**
  - *UROLOGICAL - TREATMENT - PROSTATE*

## 2.2 Amendments

New or amended text is marked in **green highlight**. Text that has been deleted is **marked with a strikethrough**. Where a **yellow highlight** is used, this denotes that the field has been moved to a new group from v7.0 to v8.0. Full details of all the amendments are provided in the COSD data set v8.0 and user guide v8.0.

The amendments below are in three sections, Substantial, Cosmetic and Schema as follows:

### 2.2.1 Substantial amendment changes

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
<b>Start of repeating item - Metastatic Site</b>						
Multiple occurrences of this item are permitted						
CR1590	CORE - NON PRIMARY CANCER PATHWAY ROUTE	METASTATIC SITE	The site of the metastatic disease, if any, at diagnosis.  More than one site can be recorded	an2	02	Brain
					03	Liver
					04	Lung
					<del>06</del>	<del>Multiple metastatic sites-</del>
					07	Unknow n metastatic site
					08	Skin
					09	Distant lymph nodes
					10	Bone (excluding Bone Marrow )
					11	Bone marrow
					12	Regional lymph nodes
					98	Other metastatic site
99	Other metastatic site					
<b>End of repeating item - Metastatic Site</b>						

[CR1590] has been reviewed by both CWT and COSD developers to enable all metastatic sites to be recorded making a multiple repeating data-item. In addition [06-Multiple Metastatic Sties] has been removed and [12-Regional Lymph Nodes] added, finally it have been moved from CORE Diagnosis to CORE - Non Primary Patient Pathway Route.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
<b>Start of repeating item - Metastatic Site</b>						
Multiple occurrences of this item are permitted						
CR6970	CORE - DIAGNOSIS	METASTATIC SITE	The site of the metastatic disease, if any, at diagnosis.  More than one site can be recorded	an2	02	Brain
					03	Liver
					04	Lung
					<del>06</del>	<del>Multiple metastatic sites-</del>
					07	Unknow n metastatic site
					08	Skin
					09	Distant lymph nodes
					10	Bone (excluding Bone Marrow )
					11	Bone marrow
					12	Regional lymph nodes
					98	Other metastatic site
99	Other metastatic site					
<b>End of repeating item - Metastatic Site</b>						

[CR6970] enables the recording of the Metastatic site more accurately within the primary pathway.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
<b>Start of repeating item - Type of Tissue Banked at Diagnosis</b>						
CT7020	CORE - DIAGNOSIS - ADDITIONAL ITEMS	TYPE OF TISSUE BANKED AT DIAGNOSIS	Indicate what tissue was banked at diagnosis	an1	1	Tumour
					2	Blood
					3	CSF
					4	Bone Marrow
					5	Urine
<b>End of repeating item - Type of Tissue Banked at Diagnosis</b>						

[CT7020] has moved from CTYA into CORE - Diagnosis Additional Items, as these could be relevant to more than just CTYA cases, and had an additional attribute added (5 - Urine), on the advice of clinical experts.

Cancer Outcomes and Services Data set (COSD) version 8.0 – Change Request

Data Item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR2050	CORE - CLINICAL NURSE SPECIALIST + RISK FACTOR ASSESSMENT	CLINICAL NURSE SPECIALIST INDICATION CODE	Record if and when the patient saw an appropriate site specific clinical nurse specialist.	an2	Y1	Yes - Clinical Nurse Specialist present when PATIENT given diagnosis
					Y3	Yes - Clinical Nurse Specialist not present when PATIENT given diagnosis but saw PATIENT during same Consultant Clinic Session
					Y4	Yes - Clinical Nurse Specialist not present during Consultant Clinic Session when PATIENT given diagnosis but saw PATIENT at other time
					Y5	Yes - Clinical Nurse Specialist not present when PATIENT given diagnosis but the patient was seen by a trained member of the Clinical Nurse Specialist team
					NI	No - PATIENT not seen at all by Clinical Nurse Specialist but Clinical Nurse Specialist informed of diagnosis
					NN	No - PATIENT not seen at all by Clinical Nurse Specialist and Clinical Nurse Specialist not informed of diagnosis
					99	Not Known (Not recorded)

[CR2050] has a new attribute added to help accurately record the CNS activity.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR1290	CORE - CLINICAL TRIALS	PATIENT TRIAL STATUS (CANCER)	An indication of whether a PATIENT who is eligible for a cancer CLINICAL TRIAL is taking part in it.	an2	EE	<del>PATIENT eligible, consented to and entered trial</del>
					ED	<del>PATIENT eligible, declined trial</del>
					01	PATIENT approached, consented to and entered trial
					02	PATIENT approached, declined trial
					03	PATIENT approached, consented, failed screening
					09	Not Known (Not Recorded)

[CR1290] has been amended to make the reporting of a patient clinical trial status more clinically accurate.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR1260	CORE - CLINICAL TRIALS	CANCER CLINICAL TRIAL TREATMENT TYPE	The type of treatment covered by a cancer CLINICAL TRIAL.	an2	01	Surgery
					02	Chemotherapy
					03	Hormone therapy
					04	Immunotherapy
					05	Radiotherapy
					06	Combination treatment
					07	Observational study
					98	Other

[CR1260] has had an additional attribute (7 - Observational Study) at the request of the COSD Advisory Board expert members and 'Other' has changed to 98.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR1340	CORE - TREATMENT	CANCER TREATMENT EVENT TYPE	The treatment event reached during a cancer patient pathway.	an2	01	First Definitive Treatment for a new primary cancer
					02	Second or subsequent treatment for a new primary cancer
					03	Treatment for a local recurrence of a primary cancer
					04	Treatment for a regional recurrence of cancer
					05	Treatment for a distant recurrence of cancer (metastatic disease)
					06	Treatment for multiple recurrence of cancer (local and/or regional and/or distant)
					07	First treatment for metastatic disease following an unknown primary cancer
					08	Second or subsequent treatment for metastatic disease following an unknown primary cancer
					09	Treatment for relapse of primary cancer (second or subsequent)
					10	Treatment for progression of primary cancer (second or subsequent)

[CR1340] amended attributes and data item description to meet CWT data set changes.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR0680	CORE - TREATMENT	CANCER TREATMENT INTENT	The original intention of the cancer treatment provided during a Cancer Care Spell.  * Disease Modification is Drug Specific ** Diagnostic and Staging are Surgery Specific	an2	G	Curative
					D	Diagnostic
					S	Staging
					P	Palliative
					01	Curative
					02	Palliative
					03	Disease Modification *
					04	Diagnostic **
					05	Staging **
08	Other					
09	Not Known					

[CR0680] has been re-designed with the advice and support of CWT, to provide a more consistent and accurate level of 'Cancer Treatment Intent' reporting, and works in conjunction with [CR6540]. The Systemic Anti-Cancer Therapy data set (SACT) and the Radiotherapy Data set (RTDS) will in time also align with these data items.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CO5290	COLORECTAL - PATHOLOGY	RESPONSE TO PREOPERATIVE THERAPY	If preoperative therapy was given what was the response (four tier system, similar to that described by Ryan et al)	an1	4	No residual tumour cells/mucous lakes only
					2	Minimal residual cancer
					3	No marked regression
					4	No viable tumour cells (fibrosis or mucus lakes only)
					5	Single cells or scattered small groups of cancer cells
					6	Residual cancer outgrowth by fibrosis
					7	Minimal or no regression (extensive residual tumour)

[CO5290] has been updated to meet changed to the Royal College of Pathologists, 'Core' clinical data set.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
GY7000	GYNAECOLOGY - SURGERY & OTHER PROCEDURES	SURGEON GRADE	Grade of senior surgeon present at operation Note: 'Colposcopist - NOS Where the procedure is a colposcopy, this may be a qualified colposcopist who is not a surgeon	an1	S	Subspecialist Gynaecological Oncologist
					C	Consultant Gynaecologist (not subspecialist)
					F	<del>Sub-Specialty Fellow</del>
					A	<del>Associate Specialist / Staff Grade</del>
					N	Non-Training Sub-Consultant Grade
					R	<del>SPR / ST3+</del>
					Q	<del>SHO / ST1 or ST2</del>
					T	Trainee including Subspecialty Fellow and ST Trainee
					G	General Surgeon / other surgical specialty
Z	Colposcopist NOS					

[GY7000] after clinical review, the attributes for this data item have been amended to help improve the data completeness and accuracy.

## 2.2.2 Cosmetic amendment changes

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format
CR0020	CORE - PATIENT IDENTITY DETAILS	LOCAL PATIENT IDENTIFIER*	<p>*For linkage purposes NHS NUMBER and/or LOCAL PATIENT IDENTIFIER (EXTENDED) is required.</p> <p>This is a number used to identify a PATIENT uniquely within a Health Care Provider. It may be different from the PATIENT's casenote number and may be assigned automatically by the computer system.</p> <p>LOCAL PATIENT IDENTIFIER (EXTENDED) is used where IT systems have a LOCAL PATIENT IDENTIFIER which is longer than 10 characters and LOCAL PATIENT IDENTIFIER cannot be used for data submission.</p>	min an1 max an20

[CR0020] Format change to min an1 max an20.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format
CR1410	CORE - REFERRALS	ORGANISATION SITE IDENTIFIER (PROVIDER FIRST SEEN)	The ORGANISATION IDENTIFIER of the Organisation Site of the Health Care Provider at the first contact with the PATIENT.	min an5 max an9
CR1450	CORE - TREATMENT	ORGANISATION SITE IDENTIFIER (OF PROVIDER CANCER TREATMENT START DATE)	The ORGANISATION IDENTIFIER of the Organisation Site where the TREATMENT START DATE FOR CANCER is recorded.	min an5 max an9

[CR1410] and [CR1450] have had a change to the field name, description and data dictionary name as per the changes to (ANANA) - please refer to SCCI0090 for more details. These data have been corrected within CWT and COSD.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format
CR0030	CORE - PATIENT IDENTITY DETAILS	ORGANISATION IDENTIFIER (CODE OF PROVIDER)	The ORGANISATION IDENTIFIER of the Organisation acting as a Health Care Provider. (an6 not applicable to COSD)	an3 or an5
CR1400	CORE - REFERRALS	ORGANISATION SITE IDENTIFIER (PROVIDER FIRST CANCER SPECIALIST)	The ORGANISATION IDENTIFIER of the Organisation Site where the PATIENT is first seen by an appropriate cancer specialist on the DATE FIRST SEEN (CANCER SPECIALIST).	min an5 max an9
CR0310	CORE - IMAGING	ORGANISATION SITE IDENTIFIER (OF IMAGING)	This is the ORGANISATION IDENTIFIER of the Organisation site where the imaging took place.	min an5 max an9
CR6230	CORE - DIAGNOSIS	ORGANISATION SITE IDENTIFIER (OF DIAGNOSIS)	The ORGANISATION IDENTIFIER of the Organisation site where the PATIENT DIAGNOSIS took place.	min an5 max an9
CR3090	CORE - MDT	ORGANISATION SITE IDENTIFIER OF MULTIDISCIPLINARY TEAM MEETING	The ORGANISATION IDENTIFIER of the Organisation Site where the Multidisciplinary Team Meeting took place. (For joint MDT meetings which cover more than one hospital more than one code may be recorded)	min an5 max an9
CR6140	CORE - MOLECULAR AND BIOMARKERS - GERMLINE TESTING FOR CANCER PREDISPOSITION	ORGANISATION IDENTIFIER OF REPORTING REGIONAL GENETICS LABORATORY	The ORGANISATION IDENTIFIER of the Organisation where the reporting laboratory is based	min an3 max an5
CR6200	CORE - MOLECULAR AND BIOMARKERS - SOMATIC TESTING FOR TARGETED THERAPY AND PERSONALISED MEDICINE	ORGANISATION IDENTIFIER OF REPORTING LABORATORY	The ORGANISATION IDENTIFIER of the Organisation where the reporting laboratory is based	min an3 max an5
CR0980	CORE - PATHOLOGY DETAILS	ORGANISATION SITE IDENTIFIER (PATHOLOGY TEST REQUESTED BY)	The ORGANISATION IDENTIFIER of the Organisation Site at which the CARE PROFESSIONAL, who requested the DIAGNOSTIC TEST REQUEST for suspected cancer, is based.	min an5 max an9
CR0800	CORE - PATHOLOGY DETAILS	ORGANISATION IDENTIFIER (OF REPORTING PATHOLOGIST)	The ORGANISATION IDENTIFIER of the Organisation at which the authorising pathologist is based.	min an3 max an5
BR4010	BREAST - REFERRALS	ORGANISATION SITE IDENTIFIER (OF CLINICAL ASSESSMENT)	The ORGANISATION IDENTIFIER where the clinical assessment of the breast for which a cancer is registered was carried out. This is based on clinical history and physical examination and will normally be the ORGANISATION IDENTIFIER of the first outpatient appointment at the breast clinic. If the patient attends more than one breast clinic, the ORGANISATION IDENTIFIER of each breast clinic where a clinical assessment was undertaken should be recorded.	min an5 max an9
SK12730	SKIN - DIAGNOSIS - MM	ORGANISATION IDENTIFIER OF REPORTING LABORATORY	This is the ORGANISATION IDENTIFIER of the ORGANISATION where the reporting laboratory is based	min an3 max an5

All the above fields have had a change to the field name, description and data dictionary name as per the changes to (ANANA) - please refer to SCCI0090 for more details.

Cancer Outcomes and Services Data set (COSD) version 8.0 – Change Request

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR0300	CORE - NON PRIMARY CANCER PATHWAY	SOURCE OF REFERRAL FOR NON PRIMARY CANCER PATHWAY	(Non Primary Cancer Pathway only.) This identifies the source of referral for a non primary cancer pathway.	an2	<b>Initiated by the CONSULTANT responsible for the Consultant Out-Patient Episode</b>	
					01	following an emergency admission
					02	following a Domiciliary Consultation
					10	following an Accident And Emergency Attendance (including Minor Injuries Units and Walk In Centres)
					11	other - initiated by the CONSULTANT responsible for the Consultant Out-Patient Episode
					<b>Not initiated by the CONSULTANT responsible for the Consultant Out-Patient Episode</b>	
					03	referral from a GENERAL MEDICAL PRACTITIONER
					92	referral from a GENERAL DENTAL PRACTITIONER
					12	referral from a GENERAL PRACTITIONER with a Special Interest (GPwSI) or dentist with a Special Interest (DwSI)
					04	referral from an Accident And Emergency Department (including Minor Injuries Units and Walk In Centres)
					05	referral from a CONSULTANT, other than in an Accident And Emergency Department
					06	self-referral
					07	referral from a Prosthetist
					13	referral from a Specialist NURSE (Secondary Care)
					14	referral from an Allied Health Professional
					15	referral from an OPTOMETRIST
16	referral from an Orthoptist					
17	referral from a National Screening Programme					
93	referral from a Community Dental Service					
97	other - not initiated by the CONSULTANT responsible for the Consultant Out-Patient Episode					

[CR0300] has moved from CORE - Cancer Recurrence/Secondary Cancer section to CORE - Non Primary Cancer Pathway, and changed its Data Item and Data Element Name.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR1550	CORE - NON PRIMARY CANCER PATHWAY	PALLIATIVE CARE SPECIALIST SEEN INDICATOR (CANCER RECURRENCE)	Record whether the patient was seen by a palliative care specialist. This would be a member of the specialist palliative care team led by a consultant in palliative medicine for a recurrence of cancer.	an1	Y	Yes
					N	No
					9	Not Known

[CR1550] has moved from CORE - Cancer Recurrence/Secondary Cancer section to CORE - Non Primary Cancer Pathway.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CT7190	CORE -NON PRIMARY CANCER PATHWAY - ALL/AML/MPAL	RELAPSE - METHOD OF DETECTION	Indicate the method of detection for the patients relapse	an1	1	Morphology
					2	Flow
					3	Molecular
					4	Clinical Examination
					9	Other

[CT7190] has moved from CTYA to CORE- Non Primary Cancer Pathway - AML/AM/MPAL on the advice of specialist clinical teams. This should help improve completeness and may be applicable to more than CTYA patients.

Data item No.	Data Item Section	Data Item Name
CT6060	CORE - DIAGNOSIS - ADDITIONAL ITEMS	PRIMARY DIAGNOSIS SUBSIDIARY COMMENT
Start of repeating item - Secondary Diagnosis (ICD)		
CT6070	CORE - DIAGNOSIS - ADDITIONAL ITEMS	SECONDARY DIAGNOSIS (ICD)
End of repeating item - Secondary Diagnosis (ICD)		
CT6080	CORE - DIAGNOSIS - ADDITIONAL ITEMS	OTHER SIGNIFICANT DIAGNOSIS SUBSIDIARY COMMENT
CT6090	CORE - DIAGNOSIS - ADDITIONAL ITEMS	FAMILIAL CANCER SYNDROME
CT6100	CORE - DIAGNOSIS - ADDITIONAL ITEMS	FAMILIAL CANCER SYNDROME SUBSIDIARY COMMENT
CT6990	CORE - DIAGNOSIS - ADDITIONAL ITEMS	BANKED TISSUE AT DIAGNOSIS

All the above data items have been moved from CTYA into CORE - Diagnosis Additional Items, as these could be relevant to more than just CTYA cases.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format
CR0520	CORE - STAGING	T CATEGORY (FINAL PRETREATMENT)	T CATEGORY (FINAL PRETREATMENT) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the size and extent of the primary tumour before treatment.	max an15
CR0540	CORE - STAGING	N CATEGORY (FINAL PRETREATMENT)	N CATEGORY (FINAL PRETREATMENT) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the absence or presence and extent of regional lymph node metastases before treatment.	max an15
CR0560	CORE - STAGING	M CATEGORY (FINAL PRETREATMENT)	M CATEGORY (FINAL PRETREATMENT) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the absence or presence of distant metastases pre treatment.	max an15
CR0580	CORE - STAGING	TNM STAGE GROUPING (FINAL PRETREATMENT)	Record the overall clinical TNM stage grouping of the tumour, derived from each T, N and M component prior to treatment. This classification is based on all the evidence available to the clinician(s) with responsibility for assessing the patient and for the patient's treatment plan. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant examinations.  The overall pretreatment TNM stage grouping indicates the tumour stage at the time the treatment plan was devised.	max an15
CR0620	CORE - STAGING	T CATEGORY (INTEGRATED STAGE)	T CATEGORY (INTEGRATED) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the size and extent of the primary tumour after treatment and/or after all available evidence has been collected.	max an15
CR0630	CORE - STAGING	N CATEGORY (INTEGRATED STAGE)	N CATEGORY (INTEGRATED) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the absence or presence and extent of regional lymph node metastases after treatment and/or after all available evidence has been collected.	max an15
CR0640	CORE - STAGING	M CATEGORY (INTEGRATED STAGE)	M CATEGORY (INTEGRATED) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the absence or presence of distant metastases after treatment and/or after all available evidence has been collected.	max an15
CR0610	CORE - STAGING	TNM STAGE GROUPING (INTEGRATED)	Record the overall TNM stage grouping of the tumour, derived from each T, N and M component after treatment. This classification is based on all the evidence available to the clinician(s) with responsibility for assessing the patient. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant examinations.  The overall integrated TNM stage grouping indicates the tumour stage after treatment and/or after all available evidence has been collected.	max an15
CR2070	CORE - STAGING	TNM EDITION NUMBER (STAGING)	The AJCC or UICC edition number used for Tumour, Node and Metastasis (TNM) staging for cancer diagnosis.	max an2

[CR0520], [CR0540], [CR0560], [CR0580], [CR0620], [CR0630], [CR0640], [CR0610] & [CR2070] have now been expanded to allow both UICC and AJCC codes to be submitted as required, including a format extension to allow for changes to TNM8.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
CR1340	CORE - TREATMENT	CANCER TREATMENT EVENT TYPE	The treatment event reached during a cancer patient pathway for primary, recurrent or metastatic cancer.	an2	01	First Definitive Treatment for a new primary cancer
					02	Second or subsequent treatment for a new primary cancer
					03	Treatment for a local recurrence of a primary cancer
					04	Treatment for a regional recurrence of cancer
					05	Treatment for a distant recurrence of cancer (metastatic disease)
					06	Treatment for multiple recurrence of cancer (local and/or regional and/or distant)
					07	First treatment for metastatic disease following an unknown primary
					08	Second or subsequent treatment for metastatic disease following an unknown primary
					09	Treatment for relapse of primary cancer (second or subsequent)
					10	Treatment for progression of primary cancer (second or subsequent)

[CR1340] has had a change to the description, this has also been changed in both CWT and the NHS Data Model and Dictionary.

Data item No.	Data Item Section	Data Item Name
CT6130	CORE - SURGERY AND OTHER PROCEDURES - STEM CELL TRANSPLANTATION	STEM CELL INFUSION SOURCE
CT6140	CORE - SURGERY AND OTHER PROCEDURES - STEM CELL TRANSPLANTATION	STEM CELL INFUSION DONOR
CT7370	CORE - SURGERY AND OTHER PROCEDURES - STEM CELL TRANSPLANTATION	CONDITIONING REGIMEN

The above data items have all been moved from CTYA group to CORE - Surgery and Other Procedures (CCLG or Stem Cell Transplantation), on the advice of clinical experts.

Data item No.	Data Item Section	Data Item Name
CT7040	CORE - LABORATORY RESULTS - GENERAL	LDH VALUE
UR15020	CORE - LABORATORY RESULTS - GENERAL	NORMAL LDH
CT6580	CORE - LABORATORY RESULTS - GERM CELL CNS and GERM CELL NON CNS TUMOURS	BETA HUMAN CHORIONIC GONADOTROPIN (SERUM)
CT6520	CORE - LABORATORY RESULTS - GERM CELL CNS, GERM CELL NON CNS TUMOURS, HEPATOBLASTOMA and HEPATOCELLULAR CERCINOMA	ALPHA FETOPROTEIN (SERUM )

The above data items have all been moved from CTYA group to CORE - Laboratory Results, on the advice of clinical experts.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format
CR0950	CORE - PATHOLOGY DETAILS	SERVICE REPORT IDENTIFIER	A unique identifier of a SERVICE REPORT.	min an1 max an36
CR6220	CORE - PATHOLOGY DETAILS	PATHOLOGY OBSERVATION REPORT IDENTIFIER	A local identifier of an OBSERVATION REPORT. This differs from the Service Report Identifier as it identifies the specific RC Path Form used, multiple of these could be contained within a Service Report (where there are multiple tumours are identified taken).	min an1 max an36

[CR0950] & [CR6220] have had their field format length extended to an36, on the advice of clinical experts and at the request of LIMS suppliers.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format
CR0910	CORE - PATHOLOGY DETAILS	T CATEGORY (PATHOLOGICAL)	T CATEGORY (PATHOLOGICAL) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the size and extent of the primary Tumour based on the evidence from a pathological examination.	max an15
CR0920	CORE - PATHOLOGY DETAILS	N CATEGORY (PATHOLOGICAL)	N CATEGORY (PATHOLOGICAL) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the absence or presence and extent of regional lymph node metastases based on the evidence from a pathological examination.	max an15
CR0930	CORE - PATHOLOGY DETAILS	M CATEGORY (PATHOLOGICAL)	M CATEGORY (PATHOLOGICAL) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the absence or presence of distant metastases based on the evidence from a pathological examination.	max an15
CR0940	CORE - PATHOLOGY DETAILS	TNM STAGE GROUPING (PATHOLOGICAL)	TNM STAGE GROUPING (PATHOLOGICAL) is the Union for International Cancer Control (UICC) or American Joint Committee on Cancer (AJCC) code which classifies the combination of Tumour, node and metastases into stage groupings based on the evidence from a pathological examination.	max an15

[CR0910], [CR0920], [CR0930] & [CR0940] have now been expanded to allow both UICC or AJCC codes to be submitted as required, including a format extension to allow for changes to TNM8.

Data item No.	Data Item Section	Data Item Name
CT6420	SARCOMA - PATHOLOGY	SARCOMA SURGICAL MARGIN ADEQUACY

[CT6420] has been moved from CTYA to CORE - Sarcoma Pathology at the request of clinical experts.

Data item No.	Data Item Section	Data Item Name
CT7030	CNS - DIAGNOSIS - LOW GRADE GLIOMA	VISUAL ACUITY AT PRESENTATION
CT7400	CNS - DIAGNOSIS - LOW GRADE GLIOMA	VISUAL FIELDS AT PRESENTATION
CT6560	CNS - STAGING - CSF (Cerebrospinal Fluid)	CHANG STAGING SYSTEM STAGE
CT6760	CNS - STAGING - CSF (Cerebrospinal Fluid)	CHANG STAGING SYSTEM STAGE DATE
CT7390	CNS - SURGERY AND OTHER PROCEDURES - GENERAL	RESECTION STATUS
CT6530	CNS - LABORATORY RESULTS - GERM CELL CNS TUMOURS	ALPHA FETOPROTEIN (CEREBROSPINAL FLUID)
CT6550	CNS - LABORATORY RESULTS - GERM CELL CNS TUMOURS	BETA HUMAN CHORIONIC GONADOTROPIN (CEREBROSPINAL FLUID)

All of the above data items have been moved from CTYA into CNS as this is the correct parent group for them to sit in and be recorded. This should help with data collection and ascertainment.

Data item No.	Data Item Section	Data Item Name
CT7200	HAEMATOLOGY - DIAGNOSIS - MIXED PHENOTYPE ACUTE LEUKAEMIA	MIXED PHENOTYPE SYMPTOMS (AT DIAGNOSIS)
CT7240	HAEMATOLOGY - DIAGNOSIS - MIXED PHENOTYPE ACUTE LEUKAEMIA	EGIL SCORE
CT7160	HAEMATOLOGY - DIAGNOSIS - ACUTE MYELOID LEUKAEMIA	FAB CLASSIFICATION
CT7170	HAEMATOLOGY - DIAGNOSIS - ACUTE MYELOID LEUKAEMIA	PAEDIATRIC CYTOGENETIC / MOLECULAR GENETIC RISK GROUP
CT7180	HAEMATOLOGY - DIAGNOSIS - ACUTE MYELOID LEUKAEMIA	AML RISK FACTORS
CT7260	HAEMATOLOGY - DIAGNOSIS - PAEDIATRIC MYELODYSPLASIA	PAEDIATRIC MYELODYSPLASIA
CT7270	HAEMATOLOGY - DIAGNOSIS - PAEDIATRIC MYELODYSPLASIA	UNDERLYING DISEASE ASSOCIATED WITH MDS
CT7380	HAEMATOLOGY - DIAGNOSIS - PAEDIATRIC MYELODYSPLASIA	CONGENITAL ANOMALIES
CT7310	HAEMATOLOGY - DIAGNOSIS - PAEDIATRIC MYELODYSPLASIA	MYELODYSPLASIA SYMPTOMS AT DIAGNOSIS
CT7150	HAEMATOLOGY - DIAGNOSIS - ACUTE LYMPHOBLASTIC LEUKAEMIA	RISK GROUP ALLOCATION
CT6250	HAEMATOLOGY - STAGING - NON HODGKIN LYMPHOMA	MURPHY (ST JUDE) STAGE
CT6710	HAEMATOLOGY - STAGING - NON HODGKIN LYMPHOMA	MURPHY (ST JUDE) STAGE DATE
CT7110	HAEMATOLOGY - SURGERY AND OTHER PROCEDURES - ACUTE LEUKAEMIAS	PRIMARY INDUCTION FAILURE

All of the above data items have been moved from CTYA into Haematology as this is the correct parent group for them to sit in and be recorded. This should help with data collection, ascertainment and reduce duplication of data collection.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code
HA8360	HAEMATOLOGY - CANCER CARE PLAN - FOLLICULAR	FLIPI 2 INDEX SCORE	Follicular Lymphoma International Prognostic Index Score 2 (FLIPI 2), derived from age, Hb, B2M, Bone Marrow Involvement and Lymph Nodes  (See User Guide for more information)	n1	0 - 5

[HA8360] has been updated to FLIPI 2 as the old field had become clinically outdated.

Data item No.	Data Item Section	Data Item Name
CT7330	HAEMATOLOGY - LABORATORY RESULTS - MYELODYSPLASIA	BONE MARROW BLASTS
CT6240	HAEMATOLOGY - LABORATORY RESULTS - ALL/AML	CYTOGENETICS SUBSIDIARY COMMENT
CT7340	HAEMATOLOGY - LABORATORY RESULTS - PAEDIATRIC MYELODYSPLASIA	CELLULARITY
CT7350	HAEMATOLOGY - LABORATORY RESULTS - PAEDIATRIC MYELODYSPLASIA	DEB TEST
CT7360	HAEMATOLOGY - LABORATORY RESULTS - PAEDIATRIC MYELODYSPLASIA	DYSPLASTIC HAEMOPOIESIS
CT7120	HAEMATOLOGY - LABORATORY RESULTS - ACUTE LYMPHOBLASTIC LEUKAEMIA - RESPONSE	D29 BM
CT7130	HAEMATOLOGY - LABORATORY RESULTS - ACUTE LYMPHOBLASTIC LEUKAEMIA - RESPONSE	D29 MRD
CT7140	HAEMATOLOGY - LABORATORY RESULTS - ACUTE LYMPHOBLASTIC LEUKAEMIA - RESPONSE	D29 STATUS OF EXTRAMEDULLARY
CT6260	HAEMATOLOGY - LABORATORY RESULTS - NON HODGKIN LYMPHOMA	ALK-1 STATUS FOR ALCL

All of the above data items have been moved from CTYA into Haematology as this is the correct parent group for them to sit in and be recorded. This should help with data collection, ascertainment and reduce duplication of data collection.

Data item No.	Data Item Section	Data Item Name
CT6350	SARCOMA - DIAGNOSIS - RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	IRS POST SURGICAL GROUP
CT6750	SARCOMA - DIAGNOSIS - RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	IRS POST SURGICAL GROUP DATE
CT6450	SARCOMA - DIAGNOSIS - EWINGS	TUMOUR VOLUME AT DIAGNOSIS
CT6370	SARCOMA - DIAGNOSIS - RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	RHABDOMYOSARCOMA SITE PROGNOSIS CODE
CT6360	SARCOMA - LABORATORY RESULTS - RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS	CYTOGENETICS FOR ALVEOLAR RHABDOMYOSARCOMA
CT6460	SARCOMA - LABORATORY RESULTS - EWINGS	CYTOGENETICS FOR EWINGS SARCOMA

All of the above data items have been moved from CTYA into Sarcoma as this is the correct parent group for them to sit in and be recorded. This should help with data collection, ascertainment and reduce duplication of data collection.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code
LU10310	LUNG - DIAGNOSIS - NLCA	<b>DIFFUSION CAPACITY (DLCO or TLCO) RESULT</b>	The Diffusion Capacity (DLCO) or Transfer factor of the lungs for carbon monoxide (TLCO) result (% predicted)	Max n3	0-200

[LU10310] has had a change to the recordable range. The result for this test is usually less than 100%, but it is possible for it to be above 100% as it is percentage predicted.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code
LU10370	LUNG - SURGERY AND OTHER PROCEDURES - NLCA	<b>CARDIOPULMONARY EXERCISE TEST RESULT (NLCA)</b>	The Cardiopulmonary Exercise Test result (% predicted)	Max n3	0-200

[LU10370] has had a change to the recordable range. The result for this test is usually less than 100%, but it is possible for it to be above 100% as it is percentage predicted.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
LV16100	LIVER - STAGING	<b>BARCELONA CLINIC LIVER CANCER (BCLC) STAGE</b>	The Barcelona Clinic Liver Cancer (BCLC) stage includes both anatomic and non-anatomic factors and is widely used within the UK to predict prognosis and determine treatment.	an1	0	Very early
					A	Early
					B	Intermediate
					C	Advanced
LV16110	LIVER - STAGING	<b>BARCELONA CLINIC LIVER CANCER (BCLC) STAGE DATE</b>	The date on which the BARCELONA CLINIC LIVER CANCER (BCLC) STAGE was recorded	an10 cyy-mm-dd		
LV16120	LIVER - STAGING	<b>PORTAL INVASION</b>	Record whether there is tumour present in the main portal vein, or if there is tumour present in a branch of the portal vein or if there is no tumour present in the portal vein.	an1	Y	Present
					N	Not present
					1	Branch
					2	Main
					3	Not present
9	Not known					

[LV16100], [LV16110] & [LV16120] have been given new data item numbers, to distinguish that they have been moved to a new 'LIVER' section. [LV16120] has had the attributes updated on the advice of the Liver Site Specific Clinical Reference Group experts.

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
LV16300	LIVER - TREATMENT - LIVER METS & LIVER HCC	<b>ABLATIVE THERAPY TYPE</b>	Describe type of ablative (i.e. locally destructive treatment) therapy used if any	an1	N	None
					R	Radiofrequency ablation
					M	Microwave ablation
					O	Other ablative treatment
					8	Other ablative treatment
9	Not known					

[LV16300] has had both the data item number and a new attribute added after discussions with the LIVER Site Specific Clinical Reference Group.

### 2.2.3 Schema Mandation amendment changes

Data item No.	Data Item Section	Data Item Name	Format	Data Dictionary Element	Schema Specification*
CR3140	CORE - HOLISTIC NEEDS ASSESSMENT	<b>HOLISTIC NEEDS ASSESSMENT COMPLETED DATE</b>	an10 cyy-mm-dd	HOLISTIC NEEDS ASSESSMENT COMPLETED DATE	Required
CR3150	CORE - HOLISTIC NEEDS ASSESSMENT	<b>HOLISTIC NEEDS ASSESSMENT POINT OF PATHWAY</b>	an2	HOLISTIC NEEDS ASSESSMENT POINT OF PATHWAY (CANCER)	Required

[CR3140] & [CR3150] have had a change to their Schema Specification from 'Optional' to 'Required'.

## 2.3 Deletions

The following data items are deleted for the reasons stated against each item. More detail is available within the Change Control Log of COSD v8.0 (inc. Data Item No.) and should be used in conjunction with this document.

- **CR0440 DATE OF RECURRENCE (CLINICALLY AGREED)\***
  - *CORE - DIAGNOSTIC DETAILS*

[CR0440] has been removed from the data set and replaced with a new pathway route.

- **CR1580 REFERRAL TO TREATMENT PERIOD START DATE**
  - *CORE - REFERRALS*

[CR1580] has been deleted as it is only required for CWT, not Cancer Registration, but can be ascertained from monthly CWT download if required for analysis.

- **CR1540 KEY WORKER SEEN INDICATOR (CANCER RECURRENCE)**
  - *CORE - NON PRIMARY PATHWAY*

[CR1540] has been deleted as it is not appropriate in the next version of COSD.

- **CR6000 ULTRASOUND EXAMINATION RESULT**
  - *BREAST - IMAGING (MAMMOGRAM)*
- **BR4050 MAMMOGRAM RESULT**
  - *BREAST - IMAGING (MAMMOGRAM)*

[CR6000] and [BR4050] have been removed as these are only specific for breast cancer and not generic across all radiology (e.g. US). It is expected therefore that [CR6780] is a better measure and this will not affect the NCRAS breast analysis functions.

- **CR0420 MULTIDISCIPLINARY TEAM DISCUSSION INDICATOR**
  - *CORE - CANCER CARE PLAN*

[CR0420] has been deleted as it is only required for CWT, not Cancer Registration, but can be ascertained from monthly CWT download if required for analysis.

- **GY7220 DISTANCE TO SEROSA**
  - *BREAST - IMAGING (AXILLA ULTRASOUND)*

[GY7220] has been retired as it is no longer part of the RC Path core data set for endometrial cancer.

- **BR4170 INVASIVE GRADE (BREAST)**
  - *BREAST - PATHOLOGY*
- **BA3160 WHO TUMOUR GRADE (CNS)**
  - *CNS - PATHOLOGY*
- **GY7150 TUMOUR GRADE**
  - *GYNAECOLOGY - PATHOLOGY - FALLOPIAN TUBE, OVARIAN EPITHELIAL and PRIMARY PERITONEAL*
- **HN9380 HISTOLOGICAL GRADE (SALIVARY TUMOUR)**
  - *HEAD & NECK - PATHOLOGY - SALIVARY*

- **SA11120 HISTOPATHOLOGICAL TUMOUR GRADE**
  - *SARCOMA - PATHOLOGY*

All of the above grades have been deleted as they can now be collected using CR0860.

- **BA3040 FEATURES OF LARGEST LESION (RADIOLOGICAL)**
  - *CNS - IMAGING*
- **BA3060 PRIMARY DIAGNOSIS (ICD RADIOLOGICAL)**
  - *CNS - CANCER CARE PLAN*

[BA3040] & [BA3060] have been retired at the request of the SSCRG.

- **CT6210 EXTRAMEDULLARY DISEASE**
  - *CTYA - DIAGNOSIS - ACUTE LYMPHOBLASTIC LEUKAEMIA and ACUTE MYELOID LEUKAEMIA*
- **CT6220 WHITE BLOOD CELL COUNT (HIGHEST PRE TREATMENT)**
  - *CTYA - DIAGNOSIS - ACUTE LYMPHOBLASTIC LEUKAEMIA and ACUTE MYELOID LEUKAEMIA*
- **CT6230 CYTOGENETIC RISK CODE**
  - *CTYA - DIAGNOSIS - ACUTE LYMPHOBLASTIC LEUKAEMIA and ACUTE MYELOID LEUKAEMIA*
- **CT6270 ANN ARBOR STAGE**
  - *CTYA - STAGING - HODGKIN LYMPHOMA*
- **CT6720 ANN ARBOR STAGE DATE**
  - *CTYA - STAGING - HODGKIN LYMPHOMA*
- **CT6280 ANN ARBOR SYMPTOMS**
  - *CTYA - STAGING - HODGKIN LYMPHOMA*
- **CT6290 ANN ARBOR EXTRANODALITY**
  - *CTYA - STAGING - HODGKIN LYMPHOMA*
- **CT7320 BLASTS ON PB**
  - *HAEMATOLOGY - LABORATORY RESULTS - PAEDIATRIC MYELODYSPLASIA*

The above data items have been removed from the data set as they were duplicated within their parent (Haematology) group.

- **CT6380 SARCOMA TUMOUR SITE (SOFT TISSUE OTHER THAN RHABDOMYOSARCOMA)**
  - *CTYA - DIAGNOSIS - RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS*
- **CT6390 SARCOMA TUMOUR SUBSITE (SOFT TISSUE) OTHER THAN RHABDOMYOSARCOMA**
  - *CTYA - DIAGNOSIS - RHABDOMYOSARCOMA and OTHER SOFT TISSUE SARCOMAS*
- **CT6470 SARCOMA TUMOUR SITE (BONE)**
  - *CTYA - DIAGNOSIS - OSTEOSARCOMA and EWINGS*
- **CT6440 SARCOMA TUMOUR SUBSITE (BONE)**
  - *CTYA - DIAGNOSIS - OSTEOSARCOMA and EWINGS*

The above data items have been removed from the data set as they were duplicated within their parent (Sarcoma) group.

- **CT6400 PRIMARY TUMOUR SIZE (RADIOLOGICAL)**
  - *CTYA - OSTEOSARCOMA*
- **CT6410 EXTENT OF NECROSIS AFTER CHEMOTHERAPY**
  - *CTYA - OSTEOSARCOMA*

[CT6400] has been removed from the data set as it can be collected in CORE-Imaging [CR0350]. [CT6410] has been removed from the data set as it can be collected in CORE-Pathology-Sarcoma [SA11140].

- **CT6590 TNM STAGE GROUPING FOR NON CNS GERM CELL TUMOURS**
  - *CTYA - STAGING - GERM CELL NON CNS TUMOURS*

[CT6590] has been removed from the data set as the groupings are incorrect and can be collected by using CORE-Staging TNM fields.

- **CT6110 MULTIDISCIPLINARY TEAM AGE CATEGORY**
  - *CTYA - CANCER CARE PLAN*

[CT6110] has been removed from the data set as this can be done as an aliases function using [CR3080] & [CR3190].

- **HA8120 BONE MARROW BLASTS PERCENTAGE**
  - *HAEMATOLOGY - LABORATORY RESULTS - MYELODYSPLASIA*

[HA8120] has been removed from the data set as this is a duplicate of [CT7330].

- **HN9140 PLANNED POST-OPERATIVE COMMUNICATION METHOD**
  - *HEAD & NECK - PRE TREATMENT ASSESSMENT*
- **HN9150 SVR COMMUNICATION PRIMARY METHOD**
  - *HEAD & NECK - POST TREATMENT ASSESSMENT*

[HN9140] + [NH9150] have been retired from the data set after discussions with the specialist SSCRG team.

- **LU10190 SMOKING STATUS**
  - *LUNG - CANCER CARE PLAN*

[LU10190] and been removed from the data set and replaced with [CR6750].

- **SK12030 CLINICAL DIAGNOSIS (PRE-HISTOLOGICAL RESULT - SKIN)**
  - *SKIN - DIAGNOSIS - BCC, SCC & MM*
- **SK12450 FINAL EXCISION MARGIN AFTER WIDE LOCAL EXCISION**
  - *SKIN - DIAGNOSIS - MM*

All the above data items have been retired from the data set (under advice from clinical experts).

- **UG13630 NUMBER OF LIVER METASTASES (PRE-OPERATIVE IMAGING)**
  - *UPPER GI - CANCER CARE PLAN - LIVER METS*
- **UG14530 CHILD-PUGH SCORE**
  - *UPPER GI - STAGING - LIVER HCC*

- **UG14540 NUMBER OF LESIONS (RADIOLOGICAL)**
  - *UPPER GI - STAGING - LIVER HCC*
- **UG14550 PORTAL INVASION**
  - *UPPER GI - STAGING - LIVER HCC*
- **UG13250 RADIOLOGICAL PROCEDURE TYPE**
  - *UPPER GI - SURGERY AND OTHER PROCEDURES - ENDOSCOPIC OR RADIOLOGICAL PROCEDURES - LIVER CHOLANGIOCARCINOMA*
- **UG13070 INTENT FOR BILIARY STENT**
  - *UPPER GI - SURGICAL AND OTHER PROCEDURES - ENDOSCOPIC OR RADIOLOGICAL PROCEDURES - LIVER CHOLANGIOCARCINOMA*
- **UG13080 SUCCESS OF DEPLOYMENT**
  - *UPPER GI - SURGICAL AND OTHER PROCEDURES - ENDOSCOPIC OR RADIOLOGICAL PROCEDURES - LIVER CHOLANGIOCARCINOMA*
- **UG13580 TRANS ARTERIAL CHEMOEMBOLISATION**
  - *UPPER GI - TREATMENT - LIVER METS and LIVER HCC*

All the above data items have been retired from the data set (under advisement of the Liver Site Specific Clinical Reference Group) as no longer clinically relevant.

- **UG14520 BARCELONA CLINIC LIVER CANCER (BCLC) STAGE**
  - *UPPER GI - STAGING - LIVER HCC*
- **UG14570 BARCELONA CLINIC LIVER CANCER (BCLC) STAGE DATE**
  - *UPPER GI - STAGING - LIVER HCC*
- **UG13590 LIVER TRANSPLANTATION**
  - *UPPER GI - SURGICAL AND OTHER PROCEDURES - LIVER HCC*
- **UG13560 ABLATIVE THERAPY TYPE**
  - *UPPER GI - TREATMENT - LIVER METS and LIVER HCC*

All the above data items have been moved to a new section called [LIVER] under advisement of the Liver Site Specific Clinical Reference Group.

- **CR1380 PATIENT PATHWAY IDENTIFIER**
- **CR1390 ORGANISATION CODE (PATIENT PATHWAY IDENTIFIER ISSUER)**
- **CR0260 TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE**
- **CR0190 DECISION TO REFER DATE (CANCER OR BREAST SYMPTOMS)**
- **CR2020 PRIORITY TYPE CODE**
- **CR0200 CANCER REFERRAL TO TREATMENT PERIOD START DATE**
- **CR1620 CONSULTANT UPGRADE DATE**
- **CR3010 ORGANISATION SITE CODE (PROVIDER CONSULTANT UPGRADE)**
- **CR0280 WAITING TIME ADJUSTMENT (FIRST SEEN)**
- **CR0290 WAITING TIME ADJUSTMENT REASON (FIRST SEEN)**
- **CR0250 DELAY REASON COMMENT (FIRST SEEN)**
- **CR0240 DELAY REASON REFERRAL TO FIRST SEEN (CANCER OR BREAST SYMPTOMS)**
- **CR3210 REFERRAL REQUEST RECEIVED DATE (INTER-PROVIDER TRANSFER)**

All the above data are Core - Referral information which is a duplication of CWT and not required for the ongoing collection of COSD. CWT data are sent directly from the national team, so this reduces the burden of data collection on Trusts.

- **CR1420 ORGANISATION SITE CODE (PROVIDER DECISION TO TREAT CANCER)**
- **CR1430 CANCER TREATMENT PERIOD START DATE**
- **CR1440 CANCER CARE SETTING (TREATMENT)**
- **CR1460 DELAY REASON COMMENT (DECISION TO TREATMENT)**
- **CR1470 DELAY REASON (DECISION TO TREATMENT)**
- **CR1480 WAITING TIME ADJUSTMENT (TREATMENT)**
- **CR1490 WAITING TIME ADJUSTMENT REASON (TREATMENT)**
- **CR1500 DELAY REASON COMMENT (REFERRAL TO TREATMENT)**
- **CR1510 DELAY REASON REFERRAL TO TREATMENT (CANCER)**
- **CR1520 DELAY REASON COMMENT (CONSULTANT UPGRADE)**
- **CR1530 DELAY REASON (CONSULTANT UPGRADE)**
- **CR1250 CLINICAL TRIAL INDICATOR**

All the above data are Core - Treatment information which is a duplication of CWT and not required for the ongoing collection of COSD. CWT data is sent directly from the national team, so this reduces the burden of data collection on Trusts.

- **CR1560 RADIOTHERAPY PRIORITY**
- **CR1570 RADIOTHERAPY INTENT**
- **CR1140 ANATOMICAL TREATMENT SITE (RADIOTHERAPY)**

All the above data are Core - Radiotherapy information which is a duplication of either CWT and/or RTDS, and not required for the ongoing collection of COSD. Both CWT and RTDS data is sent directly from the national team, so this reduces the burden of data collection on Trusts.

- **CR1070 DRUG TREATMENT INTENT**
- **CR1080 DRUG REGIMEN ACRONYM**

All the above data are Core - Chemotherapy and Other Drugs information which are a duplication of SACT and not required for the ongoing collection of COSD. SACT data is sent directly from the national team, so this reduces the burden of data collection on Trusts.

- **CR3080 ORGANISATION CODE (GP PRACTICE RESPONSIBILITY)**
- **CR3090 ORGANISATION CODE (RESIDENCE RESPONSIBILITY)**

All the above data are Core - Demographics information which is collected from other sources, and not required for the ongoing collection of COSD. This reduces the burden of data collection on Trusts.

- **CR0360 DATE OF DIAGNOSIS (CANCER REGISTRATION)**
- **CR0170 DATE OF RECURRENCE (CANCER REGISTRATION)**

The above data are Core - Diagnosis information derived during the cancer registration process and therefore not required to be collected by Trusts or required for the ongoing collection of COSD.

- **CR0220 CARE PROFESSIONAL MAIN SPECIALTY CODE (FIRST SEEN)**

The above data are Core - Referral information derived during the cancer registration process and therefore not required to be collected by Trusts or required for the ongoing collection of COSD.

- **CR0670 CARE PROFESSIONAL MAIN SPECIALTY CODE (TREATMENT)**

The above data are Core - Treatment information derived during the cancer registration process and therefore not required to be collected by Trusts or required for the ongoing collection of COSD.

- **CR2080 RADIOTHERAPY TOTAL DOSE**
- **CR2090 RADIOTHERAPY TOTAL FRACTIONS**

All the above data are Core - Radiotherapy information which is a duplication of RTDS, and not required for the ongoing collection of COSD. RTDS data is sent directly from the national team, so this reduces the burden of data collection on Trusts.

- **CR1270 PERSON DEATH DATE**
- **CR1280 DEATH LOCATION TYPE**
- **CR3020 DEATH CAUSE IDENTIFICATION METHOD**
- **CR1300 DEATH CAUSE ICD CODE (IMMEDIATE CONDITION)**
- **CR1310 DEATH CAUSE ICD CODE (DUE TO CONDITION)**
- **CR1320 DEATH CAUSE ICD CODE (OTHER CONDITION)**
- **CR1330 DEATH CAUSE ICD CODE (CONTRIBUTING CONDITION)**

All the above data are Core - Death Details information which is a duplication of ONS death certificates, and not required for the ongoing collection of COSD. Death certification information is sent directly from ONS, so this reduces the burden of data collection on Trusts.

- **BR4025 BREAST SCREENING STATUS FOR CANCER**
- **GY7030 GYNAECOLOGY SCREENING STATUS FOR CANCER**
- **CO5000 COLORECTAL SCREENING STATUS FOR CANCER**

All the above data are site specific referral information which is a duplication of the screening status, and not required for the ongoing collection of COSD. Screening status information is sent directly from the regional screening service, so this reduces the burden of data collection on Trusts.

## **2.4 Extension of scope**

The recording of breast recurrences has been within scope since January 2013, however this process has been rewritten within v8.0. All recurrences, progression and transformation can now be recorded in a new pathway 'Non Primary Cancer Pathway', which allows for better ascertainment and data quality. In addition progression and

transformation can also be recorded within the primary pathway, with the addition of new data items to facilitate this in v8.0.

Recommendation 90 of the Achieving World-Class Cancer Outcomes, A Strategy for England 2015-20 (Cancer Taskforce Report), states that “Public Health England and NHS England have been requested to establish robust surveillance systems and if possible, mandate the collection of data on recurrent and secondary cancer occurrences for all cancers and make this available for analysis and research”. The extension and reinforcement of this scope within COSD provides this function.

Further details are provided in the COSD user guide v8.0.